All News

Investigators find that radiation equivalent to 3 CT scans prompts the growth of the p53 mutation in mice.

Top news of the week from Specialty Pharmacy Times.

A recent study found the prevalence of COPD was nearly 50% higher among patients with arthritis compared with those without arthritis, even after adjusting for sociodemographic characteristics, risk behaviors, frequent distress, and asthma status.

The FDA has granted Eli Lilly and Company approval for its nasal powder glucagon (Baqsimi) for emergency treatment of severe hypoglycemia.

If approved, tazemetostat, a first-in-class EZH2 inhibitor, would be indicated for the treatment of metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

More colorectal cancer cases are being diagnosed in adults under the age of 50, with younger adults presenting with more advanced disease than those older than 50 years.

Long-term use of ivacaftor and other drugs that correct detects in the cystic fibrosis gene could potentially prevent chronic infections from developing.

Top news of the day from across the health care landscape.

A species of deer parasites known as deer keds, or Lipoptena cervi, is more widely distributed across the United States than previously thought, according to Pennsylvania State University entomologists, who noted the parasites' potential to transmit disease-causing bacteria.

A coalition of health ministries, investigators, and the World Health Organization (WHO) has outlined the key steps to develop a global program to control scabies, a parasitic disease that affects 450 million people each year in mainly low-income countries.

About 95% of people pay less than $95 per month for Humalog and 43 percent pay $0 at the retail pharmacy. Pharmacists can help determine which insulin option will provide the lowest out-of-pocket cost for customers.

The TANGO study assessed whether adults maintained viral suppression for at least 6 months after switching to the the dolutegravir/lamivudine combination.

Officials with Valneva SE have announced initiation of a second phase 2 study for VLA15 to determine optimal dosage levels and vaccination schedule for phase 3 trials of the Lyme vaccine candidate.

Stigma around behaviors such as smoking or drinking found to effect funding for associated cancers.

There are currently no approved therapies for methylmalonic acidemia, a rare and life-threatening disease caused by mutations in the MUT gene.

Top news of the day from across the health care landscape.

Curaleaf Inc., who sells CBD products marketed to consumers as creams, oil drops, capsules, syrups, and teas, will have 15 days to formulate responses to the letter indicating how the violations will be corrected.

Rituximab-pvvr (Ruxience, Pfizer) is approved to treat non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Rituximab-pvvr (Ruxience, Pfizer) is approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Researchers achieve first success in linking a solid tumor with blood biomarkers, which is often an indicator of whether a patient with breast cancer will remain in remission.

If approved, pembrolizumab in combination with lenvatinib will be indicated for the first-line treatment of advanced unresectable hepatocellular carcinoma.

Pharmacists play an important role as part of the health care team.

Individuals with persistent HIV in the cells of their cerebrospinal fluid are more likely to experience neurocognitive impairment.

Top news of the day from across the health care landscape.

The drug is indicated for use as a short-acting human insulin to improve glycemic control in adults and pediatric patients with diabetes mellitus. It is only intended to use in acute care settings under medical supervision.

Scientific advances could lead to earlier prevention and treatment of infection, helping to avoid irreversible or severe chronic diseases.

A novel potential biomarker test could identify patients who would benefit from more advanced lung cancer screening.

Why does this woman have excessive facial and neck movements?

Top news of the day from across the health care landscape.

InvaGen’s Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg are therapeutically equivalent to Pfizer's pregabalin capsules (Lyrica).